Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 100

Results For "Act"

7958 News Found

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD
Clinical Trials | May 07, 2026

GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD

This is an exciting and meaningful milestone for GRIN Therapeutics


Merck completes $5.8 billion acquisition of Terns Pharma
News | May 07, 2026

Merck completes $5.8 billion acquisition of Terns Pharma

At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia


Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
News | May 07, 2026

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation


Eli Lilly unveils $4.5 bn Indiana expansion
News | May 07, 2026

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies


Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%
News | May 06, 2026

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms


Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility
Biopharma | May 06, 2026

Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026


Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%
News | May 06, 2026

Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%

FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter


Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal
News | May 06, 2026

Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal

The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty


Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics
News | May 06, 2026

Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics

The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue